I-Mab Unveils Strategic Global Shift with Hong Kong IPO Plans and Rebrand to NovaBridge Biosciences

I-Mab (NASDAQ: IMAB), recognized as a global biotechnology platform company, has unveiled a strategic initiative to redefine its global standing. The endeavor involves a rebranding to NovaBridge Biosciences and aims at establishing a dual listing, supplementing its NASDAQ presence with an initial public offering (IPO) on the Hong Kong Stock Exchange (HKEX). This strategic shift has its sights set on elevating I-Mab’s position as a formidable global biotech platform, pending a formal name change approval from shareholders during the Extraordinary General Meeting on October 24, 2025.

Central to I-Mab’s transformation is a novel business model that emphasizes business development and translational clinical advancement, geared towards expediting the availability of innovative medicines across global markets. Part of this strategic realignment involves the acquisition of VIS-101, an innovative bifunctional biologic that targets VEGF-A and ANG2. This acquisition promises groundbreaking therapeutic potential for conditions such as wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The acquisition will be facilitated by Visara, Inc., a newly inaugurated subsidiary with a specialized focus on ophthalmic therapeutics.

The leadership team spearheading this initiative includes newly appointed Chief Financial Officer Kyler Lei, whose expertise encompasses Hong Kong and global capital markets. The company sees immense growth prospects within the Asia Pacific biopharma sector, where more than 30% of global biopharma assets are under development, and collaborations have driven deal value beyond $80 billion.

I-Mab continues to enrich its pipeline with several promising assets:

• Givastomig, a bispecific antibody targeting Claudin 18.2 X 4-1BB, is advancing through Phase 1b gastric cancer trials, with Phase 2 slated for Q1 2026.
• Ragistomig, focusing on an anti-PD-L1 X 4-1BB bispecific antibody, continues its Phase 1b study.
• Uliledlimab, which targets CD73, is in Phase 2 trials with results anticipated in the second half of 2026.
• VIS-101 is progressing through Phase 2 and is expected to be ready for Phase 3 by 2026.

I-Mab’s ambitious plans include employing a “hub-and-spoke” model, underpinning the creation of specialized subsidiaries tailored to specific assets or therapeutic areas. This innovative approach aims to mitigate risks and foster value through strategic partnerships.

Guided by an adept leadership team, including Executive Chairman Fu Wei, CEO Sean Fu, Chief Medical Officer Phillip Dennis, and Senior Vice President of Clinical Development Claire Xu, I-Mab is poised to host a business update webinar on October 16 and 17, 2025, to elucidate its renewed business model and strategic trajectory.

The dual listing on NASDAQ and HKEX is a pivotal component of I-Mab’s global growth strategy, designed to expand its investor base and enhance trading fluidity. The details of the proposed Hong Kong listing remain contingent on market conditions and regulatory approvals.

Business Update Webinar

The Company will review its new business model, strategic focus and upcoming milestones by webcast on Thursday, October 16, 2025, and Friday, October 17, 2025

Webcast and Conference Call Details:

In English:

• Date: Thursday, October 16, 2025
• Time: 5:00 PM ET
• Dial-in number (US): 1-877-407-0784
• Dial-in number (International): 1-201-689-8560
• Webcast info: please click here

In Chinese:

• Date: Friday, October 17, 2025
• Time: 5:00 PM HKT/5:00 AM ET
• Webcast info: please click here, and note Kyler Lei as the CLSA contact

A replay of the webinar will be accessible on the Events page of the Company website for 90 days.

About I-Mab

I-Mab (NASDAQ: IMAB) is a global biotechnology platform company committed to accelerating access to innovative medicines. We combine deep business development expertise with agile translational clinical development to identify, accelerate, and advance breakthrough assets. By bridging science, strategy, and execution, I-Mab enables transformative therapies to progress rapidly from discovery toward patients in need. Following this business model change, the Company announced that it intends to change its name to NovaBridge Biosciences on October 16, 2025, which is subject to Extraordinary General Meeting (EGM) approval on October 24, 2025.

The Company’s differentiated pipeline is led by givastomig, a potential best-in-class, bispecific antibody (Claudin 18.2 x 4-1BB), and VIS-101, a second-in-class, potentially best-in-class bifunctional biologic, targeting VEGF-A and ANG2.

Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed to treat Claudin 18.2-positive gastric cancer and other gastrointestinal malignancies. I-Mab is also collaborating with its partner, ABL Bio, for the development of ragistomig, a bispecific antibody integrating PD-L1 as a tumor engager and 4-1BB as a conditional T cell activator, in solid tumors. Additionally, I-Mab owns worldwide rights outside of China to uliledlimab, an anti-CD73 antibody that targets adenosine-driven immunosuppression in cancer.

VIS-101 targets VEGF-A and ANG-2 to provide more potent and durable treatment benefits for patients with wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). VIS-101 is currently completing a large, randomized, dose-ranging Phase 2 study for wet AMD. Following completion of the Transactions, I-Mab will be the majority shareholder of Visara, and Visara will control global rights to VIS-101.

For more information, please visit https://www.i-mabbiopharma.com and follow us on LinkedIn.

Dual Listing on NASDAQ and Hong Kong Stock Exchange

More information on I-Mab’s intention to pursue an IPO in Hong Kong and seek a listing on the Hong Kong Stock Exchange (HKEX) will be forthcoming.

The timing, size, structure, and specific terms of the Proposed Offering have not been determined and remain subject to market conditions and approvals by the relevant regulatory authorities, including the HKEX (and the Listing Committee) and any other applicable regulatory bodies. There can be no assurance as to whether, when, or on what terms the Proposed Hong Kong Listing will be completed.

Subject to regulatory and corporate approvals, the Company currently expects to maintain its existing listing of American Depositary Shares (ADSs) on NASDAQ and to pursue a dual listing in the US and Hong Kong. Final decisions will be made in light of market conditions and regulatory feedback.

This announcement is for information purposes only and does not constitute, or form part of, any invitation or offer to acquire, purchase or subscribe to any securities of the Company. Shareholders and potential investors should exercise caution when dealing in the securities of the Company.